单药紫杉醇治疗老年非小细胞肺癌疗效观察

目的:观察单药紫杉醇治疗老年非小细胞肺癌(NSCLC)的疗效。方法:32例年龄65岁以上的晚期NSCLC患者,采用单药紫杉醇化疗方案,150mg/m~2 d 1,21天为1个周期,中位化疗周期数为4个,治疗2个周期以上评价疗效。结果:32例患者每例均至少接受3个周期化疗,CR2例(6.3%),PR 9例(28.1%),总有效率(CR+PR)34.4%,中位生存期9.3个月,1年生存率40.7%。副反应主要为脱发、骨髓抑制及胃肠道反应。结论:单药紫杉醇是治疗老年晚期NSCLC的较好方案,疗效较好且耐受性好。

Clinical Observation of Single-paclitaxel in treatment of elderly patients with advanced non-small cell cancer

Objective：To evaluate the effects and toxicities of single-paclitaxel in treatment of elderly patients with advanced non-small cell lung cancer（NSCLC）. Methods：Thirty-two patients〉65 years of age with previously untreated advanced NSCLC were erolled for the study .paclitaxel was administered over 3h at a dose of 150mg/m2 dl for 21 days one cycle. The median number of cycles was four （range：3~6）. Eifficacy and toxicity were evaluated after two cycles. Result：The 32 patients received at lost three cycles.The overall response rate was 34.4%.The median overall survival time was 9.3 months and the 1-year overall survival rate was 40.7%. The main side effects were myelosuppression alopecia and vomiting. Conclusions：Paclitaxel administered as a single is tolerable and effective for elderly patients with advanced non-small cell lung cancer.